

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
February 14, 2019**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Edge Therapeutics, Inc.

File No. 333-228937 - CF#37127

Edge Therapeutics, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-4 registration statement filed on December 21, 2018, as amended.

Based on representations by Edge Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

| | |
|---------------|--------------------------|
| Exhibit 10.24 | through January 25, 2024 |
| Exhibit 10.29 | through January 25, 2024 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary